Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
about
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural RearrangementsHIV-1 Protease-Substrate Coevolution in Nelfinavir ResistanceA novel substrate-based HIV-1 protease inhibitor drug resistance mechanismGag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness lossPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenAtazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesComprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 proteaseRole of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivityAltered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1Genotypic predictors of human immunodeficiency virus type 1 drug resistance.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyCurrent and Novel Inhibitors of HIV ProteaseMolecular Basis for Drug Resistance in HIV-1 ProteaseGag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacityInsertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.Dual-reporter phenotypic assay for human immunodeficiency virusesMutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTClinical significance of human immunodeficiency virus type 1 replication fitness.Improving Viral Protease Inhibitors to Counter Drug Resistance.Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsNovel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Human Immunodeficiency Virus Gag and protease: partners in resistance.Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.Role of Gag in HIV Resistance to Protease InhibitorsRole of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
P2860
Q27325362-3BD0C17C-72AC-4468-8C93-E98494587C08Q27677952-407FE69A-0158-44D9-B5B4-26820B530370Q27683192-1F9F9AAF-E194-414D-A546-7015B38BDD71Q28469113-2BFB22B3-06FA-4717-BE8E-13C4AEF8B113Q28474984-47FD895E-1807-4C49-A64F-A1ABAD8743BEQ28477151-A3B2DA7F-46F6-4A26-AACB-29D9B92EEE5CQ33935276-0B439A0B-CD6B-4D0D-80DB-BF51F417EABDQ33984365-8CCA4C59-0CF1-4C8B-8557-658A1EB0E6A2Q33990752-09F1E887-A1BE-44C2-BD5A-6797525E5A28Q34012585-4D363A65-42D3-47BE-A99A-396E839F3BA6Q34489239-3529A460-C802-46E1-B229-B8D582281A39Q34526179-B7258FFC-C18D-4F41-BA53-08E272BAEA0BQ34717635-E5062C1D-484E-4222-BBEA-9BD63502DB8AQ35024024-B784C706-DE80-46D6-A654-1EB6A209D4EDQ35091548-BFC366A5-EB90-40E4-A2A9-52DF114144F9Q35108499-51644DAE-C2DF-4931-A3EC-AC525D0727BEQ35158051-3F2438B5-0350-4CAD-A53B-3573D6A8E727Q35259915-CEF77273-DFB0-4935-89E8-C9AD6BE79DCCQ35260370-1C0EB710-481A-42B7-A2BF-A3A2AF6C755EQ35548279-82D6F365-6C15-4650-860E-00F180A56044Q35842525-10C7CBDF-9A53-4606-A3E2-484527A006C8Q35942373-2C3E813E-3DA6-4D2E-B80C-4AD030FEF405Q35950846-2B3F669C-A5E2-487B-B44A-9DE0302640E9Q36175788-49F195CC-4DAC-47B3-9903-4EF59723FF70Q36268829-51801342-7D72-4BE7-B9D1-A38763F99099Q36414162-14C3982A-F216-4101-9BFA-66E2AE078AD1Q36434250-63E98AE9-6379-400A-8E74-CAFC4EC66CC5Q36452419-5353D5E3-60DF-43E3-9C4F-7315F19943B7Q36506829-6A013D0A-4F02-45FE-9735-B76F61C35A34Q36729996-F234C3A3-EB6B-43FD-88AE-02EC9833C569Q36900010-A22529FF-8526-4390-9C44-795691088E57Q36969857-0B1143AF-D87C-4EFA-81DF-1B3987A2CA73Q37017282-B983B8A6-07B2-456D-BFAC-8A7AC7C9F637Q37127869-87D6B14D-FC44-4B2B-9401-472CD5C57CE1Q37256312-827BB898-A0A0-47F7-A043-A6852C01F570Q37410823-4B328884-581D-485D-8D0F-24D2EE3182E2Q38032330-C3D6271B-5987-4154-8B1D-B48398383EF3Q38162985-696E703D-E730-4ED9-8C61-001B01AA5776Q38615581-4C73B8C1-4281-48E8-A562-1612D61F4953Q39080554-EAEF8B45-8617-4279-AA63-6A428CDF848B
P2860
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Changes in human immunodeficie ...... proved viral fitness in vitro.
@en
Changes in human immunodeficie ...... proved viral fitness in vitro.
@nl
type
label
Changes in human immunodeficie ...... proved viral fitness in vitro.
@en
Changes in human immunodeficie ...... proved viral fitness in vitro.
@nl
prefLabel
Changes in human immunodeficie ...... proved viral fitness in vitro.
@en
Changes in human immunodeficie ...... proved viral fitness in vitro.
@nl
P2093
P2860
P1433
P1476
Changes in human immunodeficie ...... proved viral fitness in vitro.
@en
P2093
B Wendy Snowden
Chris Petropoulos
David J T Porter
Eric Furfine
Josie Wolfram
Jörg-Peter Kleim
Margaret Tisdale
Mary H Hanlon
Michael F Maguire
Naomi Richards
P2860
P304
P356
10.1128/JVI.76.15.7398-7406.2002
P407
P577
2002-08-01T00:00:00Z